GlassScriptPhysician profile
Jennifer Ng
NPI 1760756670
$6,589.60
in general payments reported to CMS, 2019-2025
33 companies · $616 in 2025
The $616 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $675 · 2021: $161 · 2022: $1,452 · 2023: $1,425 · 2024: $985 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.85 | 2019-2025 | |
| Novo Nordisk INC | $682.45 | 2019-2023 | |
| Amgen INC. | $496.86 | 2023-2025 | Repatha, Evenity |
| Lilly USA, LLC | $480.40 | 2020-2024 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $414.26 | 2022-2024 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $394.92 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $339.36 | 2019-2024 | |
| Ardelyx, INC. | $273.37 | 2023-2025 | Ibsrela |
| Pfizer INC. | $256.57 | 2019-2022 | |
| Hologic Sales and Service, LLC | $198.67 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $133.50 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $132.35 | 2023 | Opdivo |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Redhill Biopharma INC. | $124.99 | 2022 | |
| Abbott Laboratories | $124.96 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $123.81 | 2022 | |
| Aimmune Therapeutics, INC. | $123.63 | 2024 | |
| Eisai INC. | $122.06 | 2025 | |
| Gilead Sciences, INC. | $121.88 | 2023 | Vemlidy |
| Madrigal Pharmaceuticals | $121.06 | 2025 | Rezdiffra |
| Dynavax Technologies Corporation | $116.64 | 2024 | Heplisav-B |
| Therapeuticsmd, INC. | $101.67 | 2020-2022 | |
| Neurelis, INC. | $94.93 | 2022 | |
| Amarin Pharma, INC. | $85.84 | 2019 | |
| Phadia US INC. | $75.00 | 2019 | |
| Merck Sharp & Dohme LLC | $65.00 | 2019-2020 | |
| Philips North America LLC | $46.69 | 2019 | |
| Lupin INC. | $32.27 | 2020 | |
| Janssen Biotech, INC. | $29.82 | 2019-2020 | |
| Organon LLC | $27.92 | 2022-2023 | Nexplanon |
| United Therapeutics Corporation | $25.15 | 2022 | |
| Agile Therapeutics, INC. | $24.21 | 2023 | Twirla |
| Boston Scientific Corporation | $20.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.